If Curly Anderson exited center left, and a good CEO put into his place, lots of good things could happen to CRY. No, Moo Lee should not be the next CEO, because he has been too tainted by Curly.
Let's look at what could easily happen. I'm going to assume Medafor would be receptive to this too. CRY and Medafor drop all litigation. GS, the new CRY CEO, and a top notch mediator sit down in a 9' by 9' room with sterile white walls, a table, three chairs, three glasses, and one pitcher of cold water. The door is locked, and they stay there until they work things out.
Then the discussion begins. Both CEO's agree they will follow the EDA as closely as possible. If either finds out about problems the CEO's take appropriate action to fix the problem. Some cross selling is inevitable. The CEO's have the accountants work this out. If there is still a problem, both CEO's agree to let it go to binding arbitration and the arbitrator determines who pays who what.
Now look at CRY's likely EPS and likely P/E. Assuming this happened, CRY would have earnings of about $0.38 for 2010 and $0.46 for 2011. BioGlue sales would increase too because HemoStase would expose more physicians to the BioGlue product. CRY's P/E would likely be 20x. CRY's stock price would likely approach $10/share, not the current $5.50/share.
So here's the scoop. The shorts must love Curly. Shareholders should boot him out. Curly has lost the edge. Maybe this is because Curly hit his head while playing hockey on the east side of St. Paul.